PhI­II win for smok­ing ces­sa­tion treat­ment puts Achieve Life Sci­ences on path to FDA, jazzes up deal talks

A spe­cial­ty phar­ma out to bring a smok­ing ces­sa­tion treat­ment long used in Cen­tral and East­ern Eu­rope to the US says it’s cleared the fi­nal hur­dle be­fore fil­ing with the FDA.

Achieve Life Sci­ences, which is based in Seat­tle and Van­cou­ver, said its can­di­date, cytisini­cline, met the pri­ma­ry and sec­ondary end­points in a con­fir­ma­to­ry Phase III tri­al, more than a year af­ter it an­nounced a win for its first Phase III tri­al. With both six- and 12-week treat­ment cy­cles, the drug im­proved the odds that study par­tic­i­pants could quit smok­ing — and stay ab­sti­nent.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN